Investigation of Pharmacokinetics and Absolute Oral Bioavailability of BI 1015550 Administered as an Oral Dose With an Intravenous Microtracer Dose of [14C]-BI 1015550 in Healthy Male Volunteers
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 04 Apr 2023 Status changed from active, no longer recruiting to completed.
- 13 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2023 Planned End Date changed from 23 Mar 2023 to 31 Mar 2023.